Documents | Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | Guidance | NICE

Documents

A list of downloadable documents created during development.

Review proposal consultation

Review proposal consultation
Stakeholder matrix ^{MSWord 35.4 KB} 25 April 2016
Review proposal paper ^{PDF 249.49 KB} 25 April 2016

Background information

Press release information

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013 ^{PDF 168.86 KB} 24 May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination information
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document ^{PDF 291.3 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) ^{PDF 249.92 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): consultee and commentator comments on the ACD
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Roche Products ^{PDF 769.87 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome ^{PDF 101.4 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer ^{PDF 198 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing ^{PDF 24.37 KB} 22 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists ^{PDF 3.65 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO) ^{PDF 323.89 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Department of Health ^{PDF 22.15 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NHS outer north east London cluster ^{PDF 134.51 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service ^{PDF 314.8 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Southampton Health Technology Assessments Centre ^{PDF 30.24 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): comments on the ACD received from the public through the NICE website ^{PDF 49.28 KB} 25 March 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation document information
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222) information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal announcement information
Appeals received ^{PDF 300.07 KB} 25 March 2015
Initial scrutiny letter - Pharma Mar ^{PDF 285 KB} 25 March 2015
Response to scrutiny letter ^{PDF 180.36 KB} 25 March 2015
Final scrutiny letter ^{PDF 104.07 KB} 25 March 2015
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (including reviews of technology appraisal guidance 91 and 222): notice of appeal information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: evaluation report information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: evaluation report ^{PDF 2.29 MB} 23 December 2014
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination document ^{PDF 542.39 KB} 23 December 2014
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appraisal consultation information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appraisal consultation document information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): evaluation report information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): evaluation report ^{PDF 10.74 MB} 27 September 2013
Ovarian Cancer Topotecan Pegylated Liposomal Doxorubicin Hydrochloride Paclitaxel Trabectedin and Gemcitabine (Review) Assessment Report - Consultation ^{PDF 6.08 MB} 22 July 2013
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final protocol ^{PDF 329.71 KB} 18 December 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final scope (post CIM) ^{PDF 66.58 KB} 12 February 2013
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final matrix ^{PDF 66.49 KB} 28 November 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): NICE response to consultee and commentator comments on the draft scope ^{PDF 277.58 KB} 28 November 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): equality impact assessment form - scoping ^{PDF 28.58 KB} 28 November 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft scope ^{PDF 73.98 KB} 05 September 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft matrix ^{PDF 66.19 KB} 05 September 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): evaluation report
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Pre-meeting briefing ^{PDF 528.33 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report ^{PDF 453.42 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report - factual accuracy check ^{PDF 57.22 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer submission - Roche ^{PDF 2.6 MB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Clarification
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NICE clarification letter ^{PDF 85.11 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer response to the NICE clarification letter ^{PDF 350.38 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Patient group, professional group and NHS organisation submission statements
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NCRI Gynaecological CSG/RCP/RCR/ACP/JCCO ^{PDF 282.23 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome ^{PDF 107.12 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovarian Cancer Action ^{PDF 100.14 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing ^{PDF 6.95 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists ^{PDF 51.56 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer ^{PDF 91.71 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Expert written personal statements
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Marcia Hall ^{PDF 38.09 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sharon Tate ^{PDF 45.13 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sarah Blagden ^{PDF 45.14 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Louise Bayne ^{PDF 25.51 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Rajinder Nijjar ^{PDF 51.95 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Oge Chesa ^{PDF 40.09 KB} 18 December 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012 ^{PDF 47.37 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012 ^{PDF 129.46 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012 ^{PDF 50.55 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012 ^{PDF 55.44 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012 ^{PDF 46.25 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope ^{PDF 46.52 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix ^{PDF 58.14 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix ^{PDF 38.97 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope ^{PDF 147.25 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment ^{PDF 44.07 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix B - draft scope for consultation (pre-referral) August 2010

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix B - draft scope for consultation (pre-referral) August 2010 ^{PDF 47.66 KB} 11 February 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix C - provisional matrix (pre-referral) August 2010

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix C - provisional matrix (pre-referral) August 2010 ^{PDF 61.23 KB} 11 February 2011